XenoPort Inc.

Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome.
Clinical Trials Week; 11/30/2009; 768 words; Astellas Pharma Inc. and XenoPort, Inc. (NASDAQ:XNPT) announced...Astellas to XenoPort (see also XenoPort, Inc.). "We are pleased to submit...Therapy, Tics, Treatment, XenoPort Inc. This article was prepared by...

GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 XP13512 FDA Review Date to February 9, 2010.
Biotech Week; 11/25/2009; 1251 words; ...GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced...was November 9, 2009 (see also XenoPort, Inc.). The FDA determined that...Food and Drug Administration, XenoPort Inc. This article was prepared by...

FORM 8-K: XENOPORT ANNOUNCES DEFINITIVE AGREEMENT
US Fed News Service, Including US State News; 11/21/2009; 382 words; WASHINGTON, Nov. 19 -- XENOPORT, INC., Santa Clara, Calif., files...as specified in its charter is XENOPORT, INC. State of Incorporation: Delaware...Events Other Events. On Nov. 19, XenoPort, Inc. and Astellas Pharma Inc. announced...

Other News To Note.
BIOWORLD Today; 11/20/2009; 977 words; ...meganucleases were cancelled or severely restricted. o XenoPort Inc., of Santa Clara, Calif., and Astellas Pharma Inc...triggers a $5 million milestone payment from Astellas to XenoPort. The data supporting the filing comes from a successful...

CRWENews Highlights: XNPT, SMSC.
M2 Presswire; 11/19/2009; 1084 words; ...announce a stock highlight on XenoPort, Inc. (NASDAQ:XNPT), MSC (NASDAQ...Syndrome Astellas Pharma Inc. and XenoPort, Inc. (NASDAQ:XNPT) today November...Astellas to XenoPort. About XenoPort XenoPort, Inc. is a biopharmaceutical company...